Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Stephens & Co. Reiterates Overweight on Chuy’s Holdings, Maintains $33 Price Target

Stephens & Co. analyst Joshua Long reiterates Chuy's Holdings (NASDAQ:CHUY) with a Overweight and maintains $33 price target.

byBenzinga Newsdesk

February 17, 2023

1 minute read

Stephens & Co. analyst Joshua Long reiterates Chuy’s Holdings (NASDAQ:CHUY) with a Overweight and maintains $33 price target.

B of A Securities Initiates Coverage On Convey Holding Parent with Buy Rating, Announces Price Target of $15

By Benzinga Newsdesk

Today, 10:04 PM

B of A Securities analyst Michael Cherny initiates coverage on Convey Holding Parent (NYSE:CNVY) with a Buy rating and announces Price Target of $15.

CNVY

Raymond James Maintains Strong Buy on Marathon Petroleum, Raises Price Target to $165

By Benzinga Newsdesk

Today, 10:04 PM

Raymond James analyst Justin Jenkins maintains Marathon Petroleum (NYSE:MPC) with a Strong Buy and raises the price target from $155 to $165.

MPC

Analyst Ratings

Where Zimmer Biomet Holdings Stands With Analysts

By Benzinga Insights

Today, 10:04 PM

Zimmer Biomet Holdings (NYSE:ZBH) has observed the following analyst ratings within the last quarter:

ZBH

Credit Suisse Group Earlier Reported Q4 EPS $(0.87) Down From $0.40 YoY, Sales $4.97B Down From $5.78B YoY

By Benzinga Newsdesk

Today, 10:04 PM

Credit Suisse Group (NYSE:CS) reported quarterly losses of $(0.87) per share. This is a 317.5 percent decrease over earnings of $0.40 per share from the same period last year. The company reported $4.97 billion in sales

Stephens & Co. Reiterates Overweight on Chuy’s Holdings, Maintains $33 Price Target

Related Posts

B of A Securities Initiates Coverage On Convey Holding Parent with Buy Rating, Announces Price Target of $15

Raymond James Maintains Strong Buy on Marathon Petroleum, Raises Price Target to $165

Where Zimmer Biomet Holdings Stands With Analysts

Credit Suisse Group Earlier Reported Q4 EPS $(0.87) Down From $0.40 YoY, Sales $4.97B Down From $5.78B YoY